Jefferies Group’s Iovance Biotherapeutics IOVA Stock Holding History

Jefferies Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-37,900	Closed	-$418K	–	1782
2022 Q2	$418K	Buy	+37,900	New	+$497K	﹤0.01%	1071
2022 Q1	–	Sell	-239,500	Closed	-$4.57M	–	1723
2021 Q4	$4.57M	Buy	+239,500	New	+$5.27M	0.03%	488
2021 Q3	–	Sell	-300,000	Closed	-$7.81M	–	1853
2021 Q2	$7.81M	Buy	300,000 +89,900	+43%	+$2.34M	0.05%	334
2021 Q1	$6.65M	Sell	210,100 -387,100	-65%	-$16M	0.06%	288
2020 Q4	$27.7M	Buy	+597,200	New	+$23.7M	0.22%	67
2020 Q3	–	Sell	-25,000	Closed	-$686	–	1443
2020 Q2	$686	Sell	25,000 -442,900	-95%	-$14.6M	0.01%	840
2020 Q1	$14M	Buy	467,900 +407,900	+680%	+$10.8M	0.16%	96
2019 Q4	$1.66M	Sell	60,000 -53,200	-47%	-$1.21M	0.01%	1150
2019 Q3	$2.06M	Buy	113,200 +63,200	+126%	+$1.4M	0.02%	1062
2019 Q2	$1.23M	Buy	+50,000	New	+$753K	0.01%	1180
2018 Q2	–	Sell	-18,000	Closed	-$304K	–	2487
2018 Q1	$304K	Buy	+18,000	New	+$273K	﹤0.01%	1795
2016 Q1	–	Sell	-38,000	Closed	-$293K	–	2397
2015 Q4	$293K	Buy	+38,000	New	+$264K	﹤0.01%	1791

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Jefferies Group's IOVA Position: Q3 2022 in Review

Jefferies Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 121 shares — an estimated $1.34K sold.

Jefferies Group first reported a position in IOVA in Q4 2015 and held it in 11 quarters. The position peaked at $22.2M in Q4 2020. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

Jefferies Group reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Jefferies Group sold 121 Iovance Biotherapeutics shares in Q3 2022, an estimated $1.34K.
Jefferies Group first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 11 quarters.
Jefferies Group's Iovance Biotherapeutics position peaked at $22.2M in Q4 2020.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.